new oral anticoagulants (noacs) - tallahassee, fl/media/files/heart and...
TRANSCRIPT
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto)
Apixaban (Eliquis) Edoxaban (Savaysa)
Janice Lawson, MD Tallahassee Memorial Hospital
Cancer and Hematology Specialists
Disclosure
No financial conflicts of interest
Brief discussion regarding off-label use of PCCs for anticoagulant reversal
Goals of discussion
• How do the NOAC’s work – Important considerations
• FDA-approved indications • Peri-procedural management • Subpopulation considerations
FDA approval
Warfarin
Heparin
Enoxaparin
Dab
igat
ran
Fondaparinux
1930 1954 1993 2001 2010 2011 2012 2015
Riv
arox
aban
Api
xaba
n
Edo
xaba
n
Leung The Hematologist 2011
Why do the NOACs seem better than warfarin?
Weitz. Hematology 2012. 536-540
Parameter Dabigatran (Pradaxa)
Rivaroxaban (Xarelto)
Apixaban (Eliquis)
Target Thrombin Factor Xa Factor Xa
Dosing Fixed, once or twice daily (can’t crush)
Fixed, once or twice daily (with food)
Fixed, twice daily
Prodrug? Yes No No
Half-life (hr) 7-17 (wide variability) 7-13 6-14
Peak Conc (hr) 1-3 2-4 1-3
Renal/Biliary Cl 80%/20% 66%/33% 25%/75%
Potential Drug Interactions
Potent P-gp inhibitors Potent CYP3A4 and P-gp inhibitors
Potent CYP3A4 and P-gp inhibitors
Dose adjustments (afib)
CrCl 15-30: 75mg BID; CrCl<15: CI Severe hepatic dz: CI
CrCl 15-50:15mg QD CrCl<15: CI Severe hepatic dz: CI
Any 2 (>80yo, <60kg, Cr>1.5) or CrCl 15-24: 2.5 BID. Sev hepatic dz: CI
Safe in Pregnancy? No No No
Antidote? No No No
Monitoring? PTT, thrombin time Anti-Xa level, ?PT Anti-Xa level TRIALS EXCLUDED PATIENTS WITH CRCl of less than 25-30ml/min
Drug-drug interactions • NOACs are substrates for CYP3A4 and/or P-glycoprotein enzymes
• Strong dual inducers: Reduce effect – Rifampin, carbamazepine, phenytoin, phenobarbital, St. John’s wort
• Strong dual inhibitors: Increase effect – ketoconazole/itraconzaole, HIV protease inhibitors,
• Strong P-gp inhibitors: Increase effect – Amiodarone, dronedarone (multaq), verapamil, quinidine
Rivaroxaban Apixaban Edoxaban Dabigatran Interactions 3A4/P-gp 3A4/P-gp P-gp P-gp
NOACs & “Reversal” • No true reversal agents for new oral anticoagulants
– Three main antidotes for NOACs are being investigated
• FFP, cryoprecipitate, platelets, protamine NOT generally useful – Despite the fact that standard coagulation studies (PT/PTT) may be
prolonged
• Prothrombin complex concentrates (PCCs – Profilnine; Kcentra)
and/or recombinant VIIa (Novoseven) may be useful – Doesn’t reverse/NOT an antidote. NOT 100% reliable. – May help generate thrombin (HIGH concentration of factors) – Risk of thrombosis (main side effect) in an already high-risk population – To be used ONLY in life-threatening bleeding/emergent surgery
Patient Concerns: Bleeding
• Lack of reversal agents/antidotes may make some patients reluctant to use NOACs
• Life-threatening/fatal bleeding are reduced by up to 50% for NOACs vs warfarin
• Outcomes with NOAC-associated major bleeding are no worse than with warfarin
Yang. Vasc Health Risk Manag. 2014 Sarode, et al. Circulation. 2013 Majeed, et al. Thromb Haemost Medscape Education
FDA-APPROVED INDICATIONS
Atrial fibrillation VTE prophylaxis after THA/TKA VTE treatment and secondary prophylaxis
Atrial fibrillation trials
Trial Patients/ Mean CHADS2
Drug Comparator Primary Efficacy Outcome (CVA)
Primary Safety Outcome (major bleeding)
RELY 18,000/ 2.1
Dabigatran 110mg BID or 150mg BID
Warfarin 110: Noninf 150: Superior
110: less 150: same
ARISTOTLE 18,000/ 2.1
Apixaban 5mg BID*
Warfarin
Superior Less
ENGAGE AF 21,000/ 2.8
Edoxaban 30mg QD or 60mg QD
Warfarin *Both: Noninf
Less (30mg: less GI)
ROCKET 14,000/ 3.5
Rivaroxaban 20mg QD
Warfarin Noninferior Same
Connolly NEJM 2009 Patel NEJM 2011 Connolly NEJM 2011 Granger NEJM 2011
* boxed warning for patients with CrCl > 95ml/in
Dosing strategies Trial Dosing Strategies
(vs dose-adjusted warfarin to target INR 2.0-3.0)
RELY (Dabigatran)
Dabigatran 110mg BID (low) or 150mg BID (high)
ROCKET AF (Rivaroxaban)
Rivaroxaban 20mg QD Dose adjustment 15mg daily for CrCl of 30-49 ml/min
ARISTOTLE (Apixaban)
Apixaban 5mg BID Dose adjustment 2.5mg BID if 2 or more factors present 1) Age >/= 80, Body weight </= 60kg, SCr >/= 1.5 mg/dL
ENGAGE AF (Edoxaban)
Edoxaban 60mg QD (low) or 30 mg QD (high) Dose adjustment halved if 1 of the factor CrCl 30-50 ml/min, Body weight </= 60kg; OR concomitant use of p-GP inhibitor verapamil, quinidine, and dronedarone
Connolly NEJM 2009 Patel NEJM 2011 Granger NEJM 2011 Giugliano NEJM 2013
One size does NOT fit all!
THA/TKA VTE prophylaxis trials
• Primary Efficacy Outcome: Total VTE and death
– Prophylactic rivaroxaban (10mg qday, 6-8 hrs post-op) superior – Pooled analysis: Non-significant trend towards increased
bleeding although still low – Biased reporting of adverse events – Could LMWH still be more appealing than rivaroxaban?
Erikkson Annu Rev Med 2011
VTE trials Trials Patient Drug Comparator Efficacy
Outcome (recurrent VTE)
Safety Outcome (major bleeding)
EINSTEIN-DVT/PE
3,500 / 4,800
Rivaroxaban 15mg BID x 3wks 20mg QD x 12mo
Enoxaparin warfarin 12mo
Non-inferior Same/Better
RECOVER 2,500 Parenteral x 9d Dabigatran 150mg BID x 6mos
Parenteral warfarin 6mo
Non-inferior Same
AMPLIFY 5,300
Apixaban 10mg BID x 1 wk 5mg BID x 6 mo
Enoxaparinwarfarin 6 mo
Non-inferior Better
HOKUSAI-VTE
8,300 Parenteral x 5-10d Edoxaban 60mg (30mg*) QD x 3-12 mo
Parenteral warfarin 6mo
Non-inferior Same/Better
EINSTEIN Inv, NEJM 2010 Schulman, NEJM 2009 Agnelli, NEJM 2013 Hokusai Inv NEJM 2013 * CrCl 30-50ml/min, wt<60kg
PERI-PROCEDURAL CONSIDERATIONS
Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis)
Peri-procedural considerations
• Balance risks of bleeding vs risks of clotting – Patients at the highest risk of peri-procedural bleeding tend
to also have an increased risk of thrombosis (elderly, active cancer)
• Evidence to support peri-procedural recs is weak – observational data, subset review of trial patients, and
consensus documents/expert opinions • Short half-life of NOACs may be an advantage
– Rapid interruption and reintroduction – Likely no need for standard peri-procedure heparin
bridging
Fawole, et al. Cleve Clin J Med. 2013; 80(7): 443-51
Lab assessment
Dabigatran (Pradaxa)
Rivaroxaban (Xarelto)
Apixiban (Eliquis)
PT
Less useful (higher Rx conc)
May be useful (variably sensitive)
Not useful
aPTT Useful (less sensitive)
Not useful Not useful
Thrombin time Useful Not useful Not useful
Anti-Xa assay Not useful Useful Useful • Labs may be useful for qualitative assessment, but not for
quantitative use (ie. not for monitoring levels)
Garcia. J of Thromb and Haem. 2012; 11: 245-252 Fawole, et al. Cleve Clin J Med. 2013; 80 (7): 443-451
How about restarting?
Connolly. J Thromb Thrombolysis. 2013; 36: 212-222
• For patients at high risk for thromboembolism, consider administering a reduced dose of NOAC on the evening after surgery and on POD #1:
Dabigatran, 75mg qday; Rivaroxaban, 10mg qday; or Apixiban 2.5mg bid
• In general, no need for post-operative heparin or LMWH bridging, unless patient’s status precludes taking oral medications or if there are concerns about absorption.
Elderly Antiplatelet therapy Cancer patients
SUBPOPULATIONS
Elderly
• Patients in clinical trials have been younger than those in practice – RELY (dabi): 40% age >/= 75 – ROCKET (riva): 25% age >/= 78
– But how many of our patients are >/= 80?
• Intrinsic factors that increase their risk of bleeding
– Falls – Low body weight (</= 60 kg) – Comorbidities (renal impairment, hepatic dysfunction, malignancy,
less buffering capacity in the GI tract, capillary fragility) – Need to follow more closely
Schulman Thrombosis Research 2013 Maddula J Thromb Thrombolysis 2013
Age and Efficacy/Safety
Schulman Thrombosis Research 2013 Eikelboom Circulation 2011
Antiplatelet therapy Role of “Triple Therapy:” • Atrial fibrillation with concomitant CAD requiring PCI is present in 20-30% of patients with atrial fibrillation • Requirement of dual antiplatelet regimen (ASA + ADP inhibitor – clopidogrel - to prevent in-stent thrombosis) in addition to anticoagulation for CVA prevention
Data is Limited: •Aspirin (<100mg/d):
–RE-LY (Dabi) 20%, ROCKET (Riva) 35%, ARISTOTLE (Apixa) 30%
•Patients on dual antiplatelet therapy were excluded from ROCKET (Riva) and ARISTOTLE (Apixa)
Huber, Am Heart J 2014; Schulman ,Thrombosis Research 2013; Furie, Stroke 2012
Triple Therapy Data from ACS patients •ATLAS ACS2-TIMI 51 – Rivaroxaban (2.5mg or 5mg bid) + standard medical therapy (ASA +/- thienopyridine)
– Both doses increased the rates of major bleeding and ICH
•APPRAISE2 – Apixaban + ASA +/- thienopyridine for ACS. – Stopped early due to increased major bleeding and no significant
reduction in recurrent ischemic events.
•PIONEER AF-PCI Trial - Rivaroxaban + DAPT vs Warfarin + DAPT ( d/c of thienopyridine) vs Rivaroxaban + clopidogrel (Rivaroxaban doses: 2.5 mg bid, 10/15mg qday)
Huber, Am Heart J 2014; ClinicalTrials.gov: NCT01830543
Cancer Patients • Up to 20% of all cancer patients (2nd leading cause of death) • NOACs appeared at least as effective as warfarin
• Some points to remember:
– Approx 5% or less of patients enrolled in NOAC trials had cancer – Comparison arm warfarin, not LMWH (standard of care) – Concern about drug-drug interactions (biologics) – Chemotherapy related GI toxicities (compliance and absorption) – None of the trials were dedicated VTE in cancer trials
• Rivaroxaban vs dalteparin (Select-d trial) • Edoxaban vs dalteparin
Current opinion: Insufficient data to support NOACs in the upfront management of VTE in cancer patients.
Efficacious Safe Convenient
What DO we know?
What DON’T we know? • Effective in real world settings?
– 20% non-adherence negative impact on efficacy? - Cost
• Long term data? – Short term follow-up in clinical trials (~2 years) vs 50 years for
warfarin
• Is lack of monitoring a good thing?
– Lost opportunity for repetitive patient education? – Prescribe-and-forget drug? – Average time spent educating patient on rationale, efficacy, and safety
of new med is < 1 minute*
* Tarn Patient Educ Counsel 2008.